Skip to main content
Erschienen in: Annals of Surgical Oncology 11/2008

01.11.2008 | Breast Oncology

A Prospective Trial on Initiation Factor 4E (eIF4E) Overexpression and Cancer Recurrence in Node-Negative Breast Cancer

verfasst von: Neal Holm, MD, Kerry Byrnes, MD, Lester Johnson, MD, Fleurette Abreo, MD, Kenneth Sehon, MD, JoAnn Alley, MD, Carol Meschonat, MS, Quyen Chu MD, Benjamin D. L. Li, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 11/2008

Einloggen, um Zugang zu erhalten

Abstract

Background

Eukaryotic Initiation Factor 4E (eIF4E) plays a crucial role in translation control. High eIF4E increase in tumor specimens independently predicted recurrence by multivariate analysis. This prospective trial of node-negative only breast cancer patients was initiated to test the hypothesis that high eIF4E increase predicts cancer recurrence and death, independent of nodal status.

Methods

The trial was powered to detect a 2.4-fold increase in relative risk for cancer recurrence in 240 node-negative patients on the basis of high versus low eIF4E increase in tumor specimens (type I error = .05, statistical power = .08). eIF4E level was quantified by using Western blot test. Treatment and surveillance regimens were standardized. Primary endpoints were cancer recurrence and cancer-related death.

Results

Of the 242 patients accrued, 112 were in the low eIF4E group (<7.5-fold), 82 were in the intermediate eIF4E group (7.5- to 15-fold), and 48 were in the high eIF4E group (>15-fold). Patients in the high eIF4E group had a statistically significant higher rate of cancer recurrence and cancer-related death (P = .0001 and P ≤ .0001, log rank test). The relative risk for cancer recurrence was 2.2-fold higher in the high eIF4E group (P = .001, Cox model), and 3.7-fold higher for cancer-related death (P = .0009).

Conclusions

In node-negative breast cancer, high eIF4E increase predicted a higher rate of cancer recurrence and death. High eIF4E patients had a >2-fold increase in relative risk for cancer recurrence and nearly a 4-fold increase in relative risk for death. This supports our hypothesis that high eIF4E is an independent predictor for breast cancer outcome independent of nodal status.
Literatur
2.
Zurück zum Zitat Greene FL, Page DL, Fleming ID, et al., eds. (2002) American Joint Committee on Cancer (AJCC) Cancer Staging Manual, 6th edition. New York: Springer-Verlag Greene FL, Page DL, Fleming ID, et al., eds. (2002) American Joint Committee on Cancer (AJCC) Cancer Staging Manual, 6th edition. New York: Springer-Verlag
3.
Zurück zum Zitat Ogura S, Hodeida T, Hozumi Y, et al. Metastasis-related factors expressed in pT1 pN0 breast cancer: assessment of recurrence risk. J Surg Oncol 2007;96:46–53.PubMedCrossRef Ogura S, Hodeida T, Hozumi Y, et al. Metastasis-related factors expressed in pT1 pN0 breast cancer: assessment of recurrence risk. J Surg Oncol 2007;96:46–53.PubMedCrossRef
4.
Zurück zum Zitat Weidner N, Cady B, Goodson WH III. Pathologic prognostic factors for patients with breast carcinoma: which factors are important. Surg Oncol Clin North Am 1997;6:415–62. Weidner N, Cady B, Goodson WH III. Pathologic prognostic factors for patients with breast carcinoma: which factors are important. Surg Oncol Clin North Am 1997;6:415–62.
5.
Zurück zum Zitat DeBenedetti A, Graff JR. eIF-4E expression and its role in malignancies and metastases. Oncogene 2004;23:3189–99.CrossRef DeBenedetti A, Graff JR. eIF-4E expression and its role in malignancies and metastases. Oncogene 2004;23:3189–99.CrossRef
6.
Zurück zum Zitat Graff J, Konicek B, Carter J, et al. Targeting initiation factor 4e for cancer therapy. Cancer Res 2008;68:631–4.PubMedCrossRef Graff J, Konicek B, Carter J, et al. Targeting initiation factor 4e for cancer therapy. Cancer Res 2008;68:631–4.PubMedCrossRef
7.
Zurück zum Zitat Mamane Y, Petroulakis E, Rong L, et al. eIF4E-from translation to transformation. Oncogene 2004;23:3172–9.PubMedCrossRef Mamane Y, Petroulakis E, Rong L, et al. eIF4E-from translation to transformation. Oncogene 2004;23:3172–9.PubMedCrossRef
8.
Zurück zum Zitat Zimmer SG, DeBenedetti A, Graff JR. Translational control of malignancy: the mRNA cap-binding protein, eIF-4E, as a central regulator of tumor formation, growth, invasion and metastasis. Anticancer Res 2000;20:1343–51.PubMed Zimmer SG, DeBenedetti A, Graff JR. Translational control of malignancy: the mRNA cap-binding protein, eIF-4E, as a central regulator of tumor formation, growth, invasion and metastasis. Anticancer Res 2000;20:1343–51.PubMed
9.
Zurück zum Zitat Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 2001;15:807–26.PubMedCrossRef Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 2001;15:807–26.PubMedCrossRef
10.
Zurück zum Zitat Kevil CG, DeBenedetti A, Payne DK, et al. Translational regulation of vascular permeability factor by eukaryotic initiation factor 4E: implications for tumor angiogenesis. Int J Cancer 1996;65:785–90.PubMedCrossRef Kevil CG, DeBenedetti A, Payne DK, et al. Translational regulation of vascular permeability factor by eukaryotic initiation factor 4E: implications for tumor angiogenesis. Int J Cancer 1996;65:785–90.PubMedCrossRef
11.
Zurück zum Zitat Kevil C, Carter P, Hu B, et al. Translational enhancement of FGF-2 by eIF-4 factors, and alternate utilization of CUG and AUG codons for translation initiation. Oncogene 1995;11:2339–48.PubMed Kevil C, Carter P, Hu B, et al. Translational enhancement of FGF-2 by eIF-4 factors, and alternate utilization of CUG and AUG codons for translation initiation. Oncogene 1995;11:2339–48.PubMed
12.
Zurück zum Zitat Schmidt EV. The role of c-myc in regulation of translation initiation. Oncogene 2004;23:3217–21.PubMedCrossRef Schmidt EV. The role of c-myc in regulation of translation initiation. Oncogene 2004;23:3217–21.PubMedCrossRef
13.
Zurück zum Zitat Rosenwald IB, Lazaris-Karatzas A, Sonenberg N, et al. Elevated levels of cyclin D1 in response to increased expression of eukaryotic initiation factor 4E. Mol Cell Biol 1993;13:7358–63.PubMed Rosenwald IB, Lazaris-Karatzas A, Sonenberg N, et al. Elevated levels of cyclin D1 in response to increased expression of eukaryotic initiation factor 4E. Mol Cell Biol 1993;13:7358–63.PubMed
14.
Zurück zum Zitat Rosenwald IB, Kaspar R, Rousseau D, et al. Eukaryotic translation initiation factor 4E regulates expression of cyclin D at transcriptional and posttranscriptional levels. J Biol Chem 1995;270:21176–80.PubMedCrossRef Rosenwald IB, Kaspar R, Rousseau D, et al. Eukaryotic translation initiation factor 4E regulates expression of cyclin D at transcriptional and posttranscriptional levels. J Biol Chem 1995;270:21176–80.PubMedCrossRef
15.
Zurück zum Zitat Wolfort R, DeBenedetti A, Nuthalapaty S, et al. Up-regulation of TLK1B by eIF4E overexpression predicts cancer recurrence in irradiated patients with breast cancer. Surgery 2006;140:161–9.PubMedCrossRef Wolfort R, DeBenedetti A, Nuthalapaty S, et al. Up-regulation of TLK1B by eIF4E overexpression predicts cancer recurrence in irradiated patients with breast cancer. Surgery 2006;140:161–9.PubMedCrossRef
16.
Zurück zum Zitat Byrnes KW, DeBenedetti A, Holm NT, et al. Correlation of TLK1B in elevation and recurrence in doxorubicin-treated breast cancer patients with high eIF4E everexpression. J Am Coll Surg 2007;204:925–33.PubMedCrossRef Byrnes KW, DeBenedetti A, Holm NT, et al. Correlation of TLK1B in elevation and recurrence in doxorubicin-treated breast cancer patients with high eIF4E everexpression. J Am Coll Surg 2007;204:925–33.PubMedCrossRef
17.
Zurück zum Zitat Rousseau D, Kaspar R, Rosenwald I, et al. Translation initiation of ornithine decarboxylase and nucleocytoplasmic transport of cyclin D1 mRNA are increased in cells overexpressing eukaryotic initiation factor 4E. Proc Natl Acad Sci U S A 1996;93:1065–70.PubMedCrossRef Rousseau D, Kaspar R, Rosenwald I, et al. Translation initiation of ornithine decarboxylase and nucleocytoplasmic transport of cyclin D1 mRNA are increased in cells overexpressing eukaryotic initiation factor 4E. Proc Natl Acad Sci U S A 1996;93:1065–70.PubMedCrossRef
18.
Zurück zum Zitat Thumma SC, Kratzke RA. Translational control: a target for cancer therapy. Cancer Lett 2007;258:1–8.PubMedCrossRef Thumma SC, Kratzke RA. Translational control: a target for cancer therapy. Cancer Lett 2007;258:1–8.PubMedCrossRef
19.
Zurück zum Zitat Duncan R, Milburn SC, Hershey JB. Regulated phosphorylation and low abundance of HeLa cell initiation factor eIF4E suggest a role in translational control. J Biol Chem 1987;262:380.PubMed Duncan R, Milburn SC, Hershey JB. Regulated phosphorylation and low abundance of HeLa cell initiation factor eIF4E suggest a role in translational control. J Biol Chem 1987;262:380.PubMed
20.
Zurück zum Zitat DeBenedetti A, Joshi-Barve S, Rinker-Schaeffer C, et al. Expression of antisense RNA against initiation factor eIF4E mRNA in HeLa cells results in lengthened cell division times, diminished translation rates, and reduced levels of both eIF4E and p220 component of eIF4F. Mol Cell Biol 1991;11:5435. DeBenedetti A, Joshi-Barve S, Rinker-Schaeffer C, et al. Expression of antisense RNA against initiation factor eIF4E mRNA in HeLa cells results in lengthened cell division times, diminished translation rates, and reduced levels of both eIF4E and p220 component of eIF4F. Mol Cell Biol 1991;11:5435.
21.
Zurück zum Zitat Mamane Y, Petroulakis E, Martineau Y, et al. Epigenetic activation of a subset of mRNAs by eIF4E explains its effects on cell proliferation. PLoS ONE 2007;2:e242.PubMedCrossRef Mamane Y, Petroulakis E, Martineau Y, et al. Epigenetic activation of a subset of mRNAs by eIF4E explains its effects on cell proliferation. PLoS ONE 2007;2:e242.PubMedCrossRef
22.
Zurück zum Zitat Kerekatte V, Smiley K, Hu B, et al. The proto-oncogene/translation factor eIF4E: a survey of its expression in breast carcinomas. Int J Cancer 1995;64:27–31.PubMedCrossRef Kerekatte V, Smiley K, Hu B, et al. The proto-oncogene/translation factor eIF4E: a survey of its expression in breast carcinomas. Int J Cancer 1995;64:27–31.PubMedCrossRef
23.
Zurück zum Zitat Li BD, Liu L, Dawson M, et al. Overexpression of eukaryotic initiation factor 4E (eIF4E) in breast carcinoma. Cancer 1997;79:2385–90.PubMedCrossRef Li BD, Liu L, Dawson M, et al. Overexpression of eukaryotic initiation factor 4E (eIF4E) in breast carcinoma. Cancer 1997;79:2385–90.PubMedCrossRef
24.
Zurück zum Zitat Scott PA, Smith K, Poulsom R, et al. Differential expression of vascular endothelial growth factor mRNA vs. protein isoform expression in human breast cancer and relationship to elF-4E. Br J Cancer 1998;77:2120–8.PubMed Scott PA, Smith K, Poulsom R, et al. Differential expression of vascular endothelial growth factor mRNA vs. protein isoform expression in human breast cancer and relationship to elF-4E. Br J Cancer 1998;77:2120–8.PubMed
25.
Zurück zum Zitat Li BD, McDonald JC, Nassar R, et al. Clinical outcome in stage I to III breast carcinoma and eIF4E overexpression. Ann Surg 1998;227:756–61.PubMedCrossRef Li BD, McDonald JC, Nassar R, et al. Clinical outcome in stage I to III breast carcinoma and eIF4E overexpression. Ann Surg 1998;227:756–61.PubMedCrossRef
26.
Zurück zum Zitat Li BD, Gruner JS, Abreo F, et al. Prospective study of eukaryotic initiation factor 4E protein elevation and breast cancer outcome. Ann Surg 2002;235:732–8.PubMedCrossRef Li BD, Gruner JS, Abreo F, et al. Prospective study of eukaryotic initiation factor 4E protein elevation and breast cancer outcome. Ann Surg 2002;235:732–8.PubMedCrossRef
27.
Zurück zum Zitat McClusky DR, Chu Q, Yu H, et al. A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-positive breast cancer. Ann Surg 2005;242:584–90.PubMed McClusky DR, Chu Q, Yu H, et al. A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-positive breast cancer. Ann Surg 2005;242:584–90.PubMed
28.
Zurück zum Zitat Dickinson AJ, Fox SB, Persad RA, et al. Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br J Urol 1994;74:762–6.PubMedCrossRef Dickinson AJ, Fox SB, Persad RA, et al. Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br J Urol 1994;74:762–6.PubMedCrossRef
29.
Zurück zum Zitat Bochner BH, Cote RJ, Weidner N, et al. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 1995;87:1603–12 Bochner BH, Cote RJ, Weidner N, et al. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 1995;87:1603–12
30.
Zurück zum Zitat Jaeger TM, Weidner N, Chew K, et al. Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. J Urol 1995;154:69–71.PubMedCrossRef Jaeger TM, Weidner N, Chew K, et al. Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. J Urol 1995;154:69–71.PubMedCrossRef
31.
Zurück zum Zitat Melhem MF, Meisler AI, Finley GG. Distribution of cells expressing myc proteins in human colorectal epithelium, polyps, and malignant tumors. Cancer Res 1992;52:5853–64.PubMed Melhem MF, Meisler AI, Finley GG. Distribution of cells expressing myc proteins in human colorectal epithelium, polyps, and malignant tumors. Cancer Res 1992;52:5853–64.PubMed
32.
Zurück zum Zitat Rosenwald IB, Rhoads DB, Callanan LD, et al. Increased expression of eukaryotic translation initiation factors eIF-4E and eIF-2 alpha in response to growth induction by c-myc. Proc Natl Acad Sci U S A 1993;90:6175–8.PubMedCrossRef Rosenwald IB, Rhoads DB, Callanan LD, et al. Increased expression of eukaryotic translation initiation factors eIF-4E and eIF-2 alpha in response to growth induction by c-myc. Proc Natl Acad Sci U S A 1993;90:6175–8.PubMedCrossRef
33.
Zurück zum Zitat Jones RM, Branda J, Johnston KA, et al. An essential E box in the promoter of the gene encoding the mRNA cap-bindingprotein (eukaryotic initiation factor 4E) is a target foractivation by c-myc. Mol Cell Biol 1996;16:4754–64.PubMed Jones RM, Branda J, Johnston KA, et al. An essential E box in the promoter of the gene encoding the mRNA cap-bindingprotein (eukaryotic initiation factor 4E) is a target foractivation by c-myc. Mol Cell Biol 1996;16:4754–64.PubMed
34.
Zurück zum Zitat Nathan CO, Sanders K, Abreo FW, et al. Correlation of p53 and the proto-oncogene eIF4E in larynxcancers: prognostic implications. Cancer Res 2000;60:3599–604.PubMed Nathan CO, Sanders K, Abreo FW, et al. Correlation of p53 and the proto-oncogene eIF4E in larynxcancers: prognostic implications. Cancer Res 2000;60:3599–604.PubMed
35.
Zurück zum Zitat Nathan CO, Liu L, Li BD, et al. Detection of the proto-oncogene eIF4E in surgical margins may predict recurrence in head and neck cancer. Oncogene 1997;15:579–84.PubMedCrossRef Nathan CO, Liu L, Li BD, et al. Detection of the proto-oncogene eIF4E in surgical margins may predict recurrence in head and neck cancer. Oncogene 1997;15:579–84.PubMedCrossRef
36.
Zurück zum Zitat Nathan CO, Franklin S, Abreo FW, et al. Analysis of surgical margins with the molecular marker eIF4E: a prognostic factor in patients with head and neck cancer. J Clin Oncol 1999;17:2909–14.PubMed Nathan CO, Franklin S, Abreo FW, et al. Analysis of surgical margins with the molecular marker eIF4E: a prognostic factor in patients with head and neck cancer. J Clin Oncol 1999;17:2909–14.PubMed
37.
Zurück zum Zitat Nathan CO, Amirghahri N, Rice C, et al. Molecular analysis of surgical margins in head and neck squamous cell carcinoma patients. Laryngoscope 2002;112:2129–40.PubMedCrossRef Nathan CO, Amirghahri N, Rice C, et al. Molecular analysis of surgical margins in head and neck squamous cell carcinoma patients. Laryngoscope 2002;112:2129–40.PubMedCrossRef
38.
Zurück zum Zitat Matthews-Greer J, Caldito G, DeBenedetti A, et al. eIF4E as a marker for cervical neoplasia. Appl Immunohistochem Mol Morphol 2005;13:367–70.PubMedCrossRef Matthews-Greer J, Caldito G, DeBenedetti A, et al. eIF4E as a marker for cervical neoplasia. Appl Immunohistochem Mol Morphol 2005;13:367–70.PubMedCrossRef
39.
Zurück zum Zitat Matthews-Greer J, DeBenedetti A, Tucker A. A model for angiogenesis in HPV-medicated cervical neoplasia. J Appl Res 2002;2:63–73. Matthews-Greer J, DeBenedetti A, Tucker A. A model for angiogenesis in HPV-medicated cervical neoplasia. J Appl Res 2002;2:63–73.
40.
Zurück zum Zitat Lee JW, Choi JJ, Lee KM, et al. eIF-4E expression is associated with histopathologic grades in cervical neoplasia. Hum Pathol 2005;36:1197–203.PubMedCrossRef Lee JW, Choi JJ, Lee KM, et al. eIF-4E expression is associated with histopathologic grades in cervical neoplasia. Hum Pathol 2005;36:1197–203.PubMedCrossRef
41.
Zurück zum Zitat Chapman AD, Kerr KM. The association between atypical adenomatous hyperplasia and primary lung cancer. Br J Cancer 2000;83:632–6.PubMedCrossRef Chapman AD, Kerr KM. The association between atypical adenomatous hyperplasia and primary lung cancer. Br J Cancer 2000;83:632–6.PubMedCrossRef
42.
Zurück zum Zitat Mori M, Rao SK, Popper HH, et al. Atypical adenomatous hyperplasia of the lung: a probable forerunner in the development of adenocarcinoma of the lung. Mod Pathol 2001;14:72–84.PubMedCrossRef Mori M, Rao SK, Popper HH, et al. Atypical adenomatous hyperplasia of the lung: a probable forerunner in the development of adenocarcinoma of the lung. Mod Pathol 2001;14:72–84.PubMedCrossRef
43.
Zurück zum Zitat Ruggero D, Montanaro L, Ma L, et al. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med 2004;10:484–6.PubMedCrossRef Ruggero D, Montanaro L, Ma L, et al. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med 2004;10:484–6.PubMedCrossRef
44.
Zurück zum Zitat Mossafa H, Damotte D, Jenabian A, et al. Non-Hodgkin’s lymphomas with Burkitt-like cells are associated with c-Myc amplification and poor prognosis. Leuk Lymphoma 2006;47:1885–93.PubMedCrossRef Mossafa H, Damotte D, Jenabian A, et al. Non-Hodgkin’s lymphomas with Burkitt-like cells are associated with c-Myc amplification and poor prognosis. Leuk Lymphoma 2006;47:1885–93.PubMedCrossRef
45.
Zurück zum Zitat Li Y, Defatta R, Sunavala-Doussabhoy G, et al. A translationally regulated Tousled Kinase phosphorylates histone H3 and confers radioresistance when overexpressed. Oncogene 2001;20:726–38.PubMedCrossRef Li Y, Defatta R, Sunavala-Doussabhoy G, et al. A translationally regulated Tousled Kinase phosphorylates histone H3 and confers radioresistance when overexpressed. Oncogene 2001;20:726–38.PubMedCrossRef
46.
Zurück zum Zitat Sunavala-Doussabhoy G, Balakrishnan SK, DeBenedetti A. The radioresistance kinase TLK1B protects the cells by promoting repair of double strand breaks. BMC Mil Biol 2005:6–19 Sunavala-Doussabhoy G, Balakrishnan SK, DeBenedetti A. The radioresistance kinase TLK1B protects the cells by promoting repair of double strand breaks. BMC Mil Biol 2005:6–19
47.
Zurück zum Zitat Norton KS, McClusky D, Debenedetti A, et al. TLK1B is elevated with eIF4E overexpression in breast cancer. J Surg Res 2004;116:98–103.PubMedCrossRef Norton KS, McClusky D, Debenedetti A, et al. TLK1B is elevated with eIF4E overexpression in breast cancer. J Surg Res 2004;116:98–103.PubMedCrossRef
48.
Zurück zum Zitat Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27–31.PubMedCrossRef Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27–31.PubMedCrossRef
49.
Zurück zum Zitat Byrnes K, White S, Chu Q, et al. High eIF4E, VEGF and microvessel density in stage I to III breast cancer. Ann Surg 2006;243:684–90.PubMedCrossRef Byrnes K, White S, Chu Q, et al. High eIF4E, VEGF and microvessel density in stage I to III breast cancer. Ann Surg 2006;243:684–90.PubMedCrossRef
Metadaten
Titel
A Prospective Trial on Initiation Factor 4E (eIF4E) Overexpression and Cancer Recurrence in Node-Negative Breast Cancer
verfasst von
Neal Holm, MD
Kerry Byrnes, MD
Lester Johnson, MD
Fleurette Abreo, MD
Kenneth Sehon, MD
JoAnn Alley, MD
Carol Meschonat, MS
Quyen Chu MD
Benjamin D. L. Li, MD
Publikationsdatum
01.11.2008
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 11/2008
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-008-0086-9

Weitere Artikel der Ausgabe 11/2008

Annals of Surgical Oncology 11/2008 Zur Ausgabe

Breast Oncology

What Is the Best?

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.